| scholarly article | Q13442814 |
| P2093 | author name string | Amy E Adams | |
| Paul A Khavari | |||
| Qun Lin | |||
| Paul B Robbins | |||
| Yakov Chudnovsky | |||
| P2860 | cites work | Developmental context determines latency of MYC-induced tumorigenesis | Q24794847 |
| Mutations of the BRAF gene in human cancer | Q27860760 | ||
| Genomic analysis of metastasis reveals an essential role for RhoC | Q28144278 | ||
| Oncogenic forms of p53 inhibit p53-regulated gene expression | Q28251120 | ||
| A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma | Q28296086 | ||
| The pathogenesis of melanoma induced by ultraviolet radiation | Q33603082 | ||
| Germline p16 mutations in familial melanoma | Q34059915 | ||
| High frequency of BRAF mutations in nevi | Q34160519 | ||
| Telomerase extracurricular activities | Q34188137 | ||
| Telomerase contributes to tumorigenesis by a telomere length-independent mechanism | Q34188701 | ||
| Genetics of melanoma predisposition | Q34203435 | ||
| Components of the Rb pathway are critical targets of UV mutagenesis in a murine melanoma model | Q34329975 | ||
| Deregulated Akt3 activity promotes development of malignant melanoma | Q34355872 | ||
| Distinct requirements for Ras oncogenesis in human versus mouse cells | Q34787097 | ||
| PTEN signaling pathways in melanoma | Q35146572 | ||
| Cutaneous melanoma--past, present, and future | Q35831179 | ||
| Genetic progression of metastatic melanoma. | Q35885361 | ||
| Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma | Q36982042 | ||
| Contribution of p16(INK4a) to replicative senescence of human fibroblasts | Q40533302 | ||
| High-Efficiency Gene Transfer and Pharmacologic Selection of Genetically Engineered Human Keratinocytes | Q40845637 | ||
| Episomal vectors rapidly and stably produce high-titer recombinant retrovirus | Q42810400 | ||
| Cadherin repertoire determines partner-specific gap junctional communication during melanoma progression | Q43878517 | ||
| A germline deletion of p14(ARF) but not CDKN2A in a melanoma-neural system tumour syndrome family | Q44810003 | ||
| NF-kappaB blockade and oncogenic Ras trigger invasive human epidermal neoplasia. | Q45982548 | ||
| CDK4 coexpression with Ras generates malignant human epidermal tumorigenesis | Q46492957 | ||
| Both products of the mouse Ink4a/Arf locus suppress melanoma formation in vivo | Q53377245 | ||
| Rebuilding the road to cancer. | Q53420421 | ||
| Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus | Q57269211 | ||
| Dominant role of the niche in melanocyte stem-cell fate determination | Q57338437 | ||
| Mutation and expression of the p53 gene in human malignant melanoma | Q72063327 | ||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 745-749 | |
| P577 | publication date | 2005-06-12 | |
| P1433 | published in | Nature Genetics | Q976454 |
| P1476 | title | Use of human tissue to assess the oncogenic activity of melanoma-associated mutations | |
| P478 | volume | 37 |
| Q37815139 | A new era: melanoma genetics and therapeutics |
| Q33561621 | A planarian p53 homolog regulates proliferation and self-renewal in adult stem cell lineages |
| Q36096818 | A prognostic signature of defective p53-dependent G1 checkpoint function in melanoma cell lines |
| Q28591778 | ARF functions as a melanoma tumor suppressor by inducing p53-independent senescence |
| Q47552989 | Activation of G protein-coupled estrogen receptor signaling inhibits melanoma and improves response to immune checkpoint blockade |
| Q41680604 | Activation of forkhead box O transcription factors by oncogenic BRAF promotes p21cip1-dependent senescence. |
| Q37847257 | Animal models of melanoma: a somatic cell gene delivery mouse model allows rapid evaluation of genes implicated in human melanoma |
| Q37086193 | BRAF kinase in melanoma development and progression. |
| Q28543370 | BRAF vs RAS oncogenes: are mutations of the same pathway equal? Differential signalling and therapeutic implications |
| Q36921234 | BRAF(E600) in benign and malignant human tumours |
| Q36021702 | BRAFV600E remodels the melanocyte transcriptome and induces BANCR to regulate melanoma cell migration |
| Q42478581 | Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells |
| Q39873596 | Braf(V600E) cooperates with Pten loss to induce metastatic melanoma |
| Q36117850 | CDKN2B Loss Promotes Progression from Benign Melanocytic Nevus to Melanoma. |
| Q80998287 | Cancer genetics: Finding the right mix |
| Q28258334 | Cancer: off by a whisker |
| Q53278200 | Carcinogen treatment in mouse selectively expressing activated N-Ras Q61K in melanocytes recapitulates metastatic cutaneous melanoma development |
| Q40630464 | Cell proliferation in cutaneous malignant melanoma: relationship with neoplastic progression |
| Q42016240 | Cellular senescence in naevi and immortalisation in melanoma: a role for p16? |
| Q27349020 | Combined targeting of BRAF and CRAF or BRAF and PI3K effector pathways is required for efficacy in NRAS mutant tumors |
| Q39939490 | Comparing in vivo pump-probe and multiphoton fluorescence microscopy of melanoma and pigmented lesions |
| Q34338564 | Cooperative interactions of PTEN deficiency and RAS activation in melanoma metastasis |
| Q33910221 | Cooperativity of oncogenic K-ras and downregulated p16/INK4A in human pancreatic tumorigenesis |
| Q26782090 | Cross-species models of human melanoma |
| Q36970648 | Cutaneous melanoma in genetically modified animals |
| Q40114129 | Defective cell cycle checkpoint functions in melanoma are associated with altered patterns of gene expression |
| Q35779541 | Dissection of RAS downstream pathways in melanomagenesis: a role for Ral in transformation. |
| Q83009690 | Drug discovery in the next decade: innovation needed ASAP |
| Q51855694 | Engineering melanoma progression in a humanized environment in vivo. |
| Q37267202 | From UVs to metastases: modeling melanoma initiation and progression in the mouse. |
| Q37270065 | GAB2 induces tumor angiogenesis in NRAS-driven melanoma. |
| Q37164581 | Gab2-mediated signaling promotes melanoma metastasis |
| Q40233574 | Genetic induction of tumorigenesis in swine. |
| Q37409032 | Genetics and genomics of melanoma |
| Q38589518 | Genetics of melanoma progression: the rise and fall of cell senescence |
| Q26851787 | Genomics of chromophobe renal cell carcinoma: implications from a rare tumor for pan-cancer studies |
| Q37045217 | Growth factors and oncogenes as targets in melanoma: lost in translation? |
| Q37453821 | Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site |
| Q35956268 | IQGAP1 and IQGAP3 Serve Individually Essential Roles in Normal Epidermal Homeostasis and Tumor Progression |
| Q37042015 | Identification of a novel subgroup of melanomas with KIT/cyclin-dependent kinase-4 overexpression |
| Q35042936 | In vivo and ex vivo epi-mode pump-probe imaging of melanin and microvasculature |
| Q42723115 | Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma |
| Q35083740 | KRAS Mouse Models: Modeling Cancer Harboring KRAS Mutations |
| Q36446127 | Knockin mice expressing a chimeric p53 protein reveal mechanistic differences in how p53 triggers apoptosis and senescence |
| Q51741544 | Lysosomes support the degradation, signaling, and mitochondrial metabolism necessary for human epidermal differentiation. |
| Q37381179 | MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer. |
| Q36828214 | Melanoma invasion - current knowledge and future directions |
| Q34826179 | Melanoma, nevogenesis, and stem cell biology |
| Q21284811 | Melanoma: from melanocyte to genetic alterations and clinical options |
| Q27024061 | Melanoma: from mutations to medicine |
| Q62067844 | Mixed versus pure variants of desmoplastic melanoma: a genetic and immunohistochemical appraisal |
| Q36422870 | Modelling cancer in human skin tissue |
| Q36301289 | Molecular targets in melanoma: strategies and challenges for diagnosis and therapy |
| Q37984547 | Narrowing the knowledge gaps for melanoma |
| Q36845724 | New technologies used in the study of human melanoma |
| Q36150711 | Non-germline genetically engineered mouse models for translational cancer research |
| Q38095892 | Obesity and melanoma: exploring molecular links |
| Q34144327 | Oncogenic NRAS cooperates with p53 loss to generate melanoma in zebrafish |
| Q41825555 | Overexpression of Akt converts radial growth melanoma to vertical growth melanoma. |
| Q53349576 | Oxygen deprivation provokes melanoma |
| Q47818895 | Pathology and genomics of pediatric melanoma: A critical reexamination and new insights. |
| Q37777015 | Pathways of oncogene-induced senescence in human melanocytic cells |
| Q36680090 | Practices and pitfalls of mouse cancer models in drug discovery. |
| Q50068807 | RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1. |
| Q37825724 | Reviewing once more the c-myc and Ras collaboration: converging at the cyclin D1-CDK4 complex and challenging basic concepts of cancer biology |
| Q36892005 | Sex steroids regulate skin pigmentation through nonclassical membrane-bound receptors |
| Q42519813 | Survivin repression by p53, Rb and E2F2 in normal human melanocytes |
| Q33806005 | Systematic Epigenomic Analysis Reveals Chromatin States Associated with Melanoma Progression |
| Q28391602 | TERT-CLPTM1L polymorphism rs401681 contributes to cancers risk: evidence from a meta-analysis based on 29 publications |
| Q38098888 | Targeting MAPK pathway in melanoma therapy |
| Q36141097 | Targeting drivers of melanoma with synthetic small molecules and phytochemicals |
| Q40007423 | Targeting the Cellular Signaling: BRAF Inhibition and Beyond for the Treatment of Metastatic Malignant Melanoma |
| Q37197419 | The role of BRAF mutation and p53 inactivation during transformation of a subpopulation of primary human melanocytes |
| Q28246658 | The somatic genomic landscape of chromophobe renal cell carcinoma |
| Q28474973 | Uncoupling of the LKB1-AMPKalpha energy sensor pathway by growth factors and oncogenic BRAF |
| Q82623062 | [Advances in molecular biology and their application in the diagnosis and treatment of melanoma] |
| Q80526287 | [Relevance of cell culture models in cutaneous tumour biology: part II: complex culture systems] |
| Q37590529 | miR-146a promotes the initiation and progression of melanoma by activating Notch signaling. |
| Q36944185 | p16INK4a expression and absence of activated B-RAF are independent predictors of chemosensitivity in melanoma tumors |
Search more.